Portrait of Nikolas Siccha

Nikolas Siccha

Bayesian statistical modelling and data analysis

I build statistical models that turn incomplete, noisy data into estimates and predictions with honest uncertainty. Typical questions: how a drug's concentration evolves across a patient population and how much individuals differ; which readings in a sensor network are implausible and why; how regions compare once small sample sizes are taken into account. Results are delivered as reproducible analyses, reports and interactive dashboards, as open-source software.

CV

since 2025Independent consultant: Bayesian pharmacometric modellingGenerable Inc.
2022 – 2026Postdoctoral research in probabilistic modellingAalto University; University of Cambridge
2021PhD in MathematicsRWTH Aachen University
2017BSc and MSc in Computational Engineering ScienceRWTH Aachen University

Glossary

Statistics and Bayesian modelling

Bayesian model
A statistical model that describes everything unknown with probabilities and updates them with the data. Its results are ranges of plausible values, not single numbers.See also: Prior, Posterior
Prior
What a Bayesian model assumes about an unknown quantity before it sees the data.
Posterior
What a Bayesian model says about an unknown quantity after it has seen the data: the plausible values and how plausible each is.
Posterior draw
One plausible set of values for a model's unknowns, drawn from the posterior. A few thousand draws together describe the posterior.
Median
The middle value: half of the plausible values lie below it and half above.
Interval
The range that contains the unknown value with the stated probability, according to the model. The plots show a 50% interval (narrow band) and a 95% interval (wide band).
Student-t distribution
A bell-shaped distribution like the normal distribution, but one that makes values far from the centre more likely.
Noise
The chance variation in data: measurement error and everything else a model does not explain.
Standard deviation
A measure of spread. For bell-shaped data about two thirds of the values lie within one standard deviation of the mean. Abbreviated SD.
Standard error
The typical size of the chance error of an estimate.
Percentage points
The difference between two percentages: from 50% to 56% is 6 percentage points.
Multilevel model
A model for many similar units, such as districts, patients or probes. It estimates each unit from its own data and from what the units have in common.See also: Pooling
Pooling
Estimating each unit partly from its own data and partly from all units together. A unit with little data leans more on the others, which steadies its estimate.
Mixed-effects model
Another name for a multilevel model, usual in pharmacometrics. Nonlinear means that the model describes a curve, such as a drug concentration over time, not a straight line.See also: Multilevel model
Small-area model
A multilevel model for regions that each have few observations. The Fay–Herriot model is the classic form.See also: Multilevel model, Pooling
Heteroscedastic
With noise whose size is not constant, for example larger at some times than at others.
Censored
Known only to lie below or above a limit. A censored analysis uses exactly that information instead of dropping the value or inventing one.
Logistic model
A model for a yes-or-no outcome. Here: the probability of a dose-limiting toxicity as a smooth S-shaped curve over the dose, with two unknown numbers.
Simulation study
An experiment on invented data whose truth is known, to see how well a method recovers it.
Monte Carlo estimate
A number computed from random draws. It carries a chance error that shrinks as the number of draws grows.

Sampling and computation

Sampler
The algorithm that produces the posterior draws of a Bayesian model.
Hamiltonian Monte Carlo
The standard sampler for models with many unknowns. It moves through the plausible values by following the slope of the posterior.
No-U-Turn sampler
A variant of Hamiltonian Monte Carlo that chooses the length of each move by itself. Abbreviated NUTS.
Chain
One independent run of the sampler. Several chains that agree are evidence that the draws describe the posterior.
Warm-up
The first part of a chain, in which the sampler tunes itself to the model. Its draws are not used.
Divergent transition
A move of the sampler that failed numerically. It warns that the draws may miss a part of the posterior.
R-hat
A check that the chains of a fit agree. Values near 1 are good; above 1.05 the fit should not be trusted without a closer look.
Effective draws
How many independent draws a chain's draws are worth. Successive draws of a chain resemble each other, so the number is smaller than the number of draws.
Mixing
How freely a chain moves through the plausible values. A chain that mixes badly stays in one region for long and needs many more draws.
Target acceptance rate
A setting of the sampler: a higher value makes it take smaller, more careful steps, at the price of more computation.
Centered and non-centered
Two equivalent ways of writing a multilevel model. Which one the sampler handles well depends on how much the data say about each unit; partly centered forms lie in between.
Reparametrization
Writing the same model in other coordinates, so that the sampler can move through it more easily. The results do not change.
Gradient
The slope of the posterior at one point. Samplers evaluate it at every step, so the number of gradient evaluations measures the computing cost.

Drugs and clinical trials

Pharmacometrics
The quantitative modelling of how drugs behave in patients: concentrations, effects and how both differ between people.
PK/PD
Pharmacokinetics and pharmacodynamics. Pharmacokinetics is what the body does to the drug (its concentration over time); pharmacodynamics is what the drug does to the body (its effects). A PK/PD model describes both.See also: Population model
Population model
A model of a whole group of patients: the typical patient, and how much individual patients differ from that.
One-compartment model
The simplest model of a drug in the body: one well-mixed volume that the drug enters and leaves.
Clearance
The volume of blood the body frees of the drug per unit of time. At the same dose, a patient with a low clearance has more drug in the body for longer.
Exposure
How much drug a patient's body sees. Here: the dose divided by the patient's clearance.
Turnover model
A model of a quantity that the body produces and removes all the time. A drug that slows the production makes the quantity fall with a delay, and it recovers when the drug is gone.
Baseline
The level of a quantity before anything acts on it: a patient's value before the dose, or a probe's usual reading without rain.
Biomarker
A measured quantity that follows the effect of a drug, such as a blood count. A safety marker is a biomarker that shows harm.
Neutrophil count
The number of neutrophils in the blood, the white blood cells that fight infections. Many cancer drugs lower it, and a very low count is dangerous.
LLOQ
Lower limit of quantification: the smallest concentration a laboratory method measures reliably. Lower values are reported only as "below the LLOQ".
Phase 1 trial
The first trial of a new drug in patients. In oncology it searches for the highest dose patients tolerate, in a few dozen patients.See also: Phase 2 trial, Phase 3 trial
Phase 2 trial
A trial in a few dozen patients that looks for first signs that the drug works, at the dose phase 1 recommended.
Phase 3 trial
The large trial that compares the drug with the standard treatment, usually in hundreds of patients. A positive phase 3 trial is the basis of an approval.
Dose-limiting toxicity
A side effect severe enough to limit the dose a patient can be given. Abbreviated DLT.
Maximum tolerated dose
The highest dose at which the share of patients with a dose-limiting toxicity stays below an agreed limit; 33% in the study shown here. Abbreviated MTD.
Cohort
A small group of patients treated at the same dose, here three, before the dose of the next group is decided.
Phase 1 design
The rule that decides the dose of the next cohort and the dose recommended at the end of a phase 1 trial.
3+3 design
The traditional phase 1 design. Three patients get a dose: after no toxicity the dose rises, after one toxicity three more patients get the same dose, and after two the dose counts as too high.
BOIN
Bayesian optimal interval design: a phase 1 design that raises, keeps or lowers the dose by comparing the toxicity rate observed at the current dose with two fixed boundaries.
CCD
Cumulative cohort design: a phase 1 design that raises, keeps or lowers the dose according to the toxicity rate observed so far at the current dose.
mTPI
Modified toxicity probability interval design: a phase 1 design that raises, keeps or lowers the dose according to which range of toxicity rates the data at the current dose support most: too low, on target or too high. mTPI-2 divides the ranges more finely.
CRM
Continual reassessment method: a phase 1 design that fits a simple dose-toxicity curve to the toxicities seen so far and gives the next cohort the dose whose estimated toxicity rate is closest to the target.
Toxicity profile
One assumed truth of a simulation: the probability of a dose-limiting toxicity at each dose.
Efficacy profile
One assumed truth of a simulation: how well the drug works at each dose.
Overall success
The probability that a drug development program succeeds: phase 1 recommends a dose that is not too toxic, and the phase 2 and phase 3 trials at that dose are both positive.
Operating characteristics
How a trial design behaves over many repetitions of the trial: how often it recommends each dose and how many patients it exposes to toxicity.

Monitoring and environment

Ambient gamma dose rate
The level of gamma radiation in the open air, from natural and artificial sources, measured continuously by a network of probes.
Rain washout
Rain carries naturally occurring radioactive particles from the air to the ground, which raises the measured dose rate for a few hours.See also: Radon decay products
Radon decay products
Short-lived radioactive atoms that form in the air when the natural gas radon decays, mainly lead-214 and bismuth-214. They emit gamma radiation and stick to dust.
Cosmic radiation
Radiation that reaches the ground from space. There is more of it at altitude, where less air lies above.
Snow water
The water a snow cover holds, given as the depth in mm of the layer it would form when melted (the snow water equivalent). Unlike the snow depth, it stays the same when the snow settles.
Attenuation
The weakening of radiation on its way through matter, such as snow or water.
Nanosievert per hour
The unit of the dose rate on this site, written nSv/h. Natural levels in Germany lie roughly between 50 and 200 nSv/h.
Pre-alarm
An automatic notice that a probe's reading is above its threshold and needs a second look.

Evaluation

Event study
A comparison of units that adopt a programme with units that have not adopted it, year by year relative to the year of adoption. Estimates near zero before adoption support the comparison.

Gaussian processes

Gaussian process
A model for an unknown smooth curve. It assumes how similar the curve is at nearby points, not a formula for its shape. Abbreviated GP.
Hilbert-space basis functions
A set of fixed wave-shaped curves whose weighted sum approximates a Gaussian process at a fraction of the computing cost. Each curve has one basis weight.
Hyperparameter
A number that sets the general behaviour of a model component and not a single value of it. For a Gaussian process: the amplitude and the length scale.
Amplitude
How far a Gaussian-process curve typically moves away from its mean.
Length scale
How far apart two points have to be before the curve can differ noticeably between them.

Software

Stan
A widely used programming language and toolkit for Bayesian models.
Julia
A programming language for scientific computing. The open-source packages on this page are written in it.
brms
A widely used R package in which a regression model is written as a short formula.